The9 expects 15%-16% stake in Nanyang Biologics after planned Nasdaq SPAC merger
NCTY•Nanyang Biologics moves closer to Nasdaq listing
The9’s investee Nanyang Biologics moved closer to a Nasdaq listing via a planned business combination with RF Acquisition Corp II.
On Aug. 19, 2026, RFAI shareholders backed the deal, clearing a key step toward trading under ticker “NYB.”
The9 expects a minority stake in the combined company
The9 expects to own about 15% to 16% of the combined Nasdaq-listed company once the transaction closes.
